All Photos(1)


Rivastigmine for system suitability

European Pharmacopoeia (EP) Reference Standard

ENA-713, S-Rivastigmine tartrate, Rivastigmine tartrate, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Empirical Formula (Hill Notation):
C14H22N2O2 · C4H6O6
CAS Number:
Molecular Weight:


pharmaceutical primary standard



Featured Industry

Pharmaceutical (small molecule)



storage temp.




InChI key


Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.


Unit quantity: 1.0114 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.


Other Notes

Sales restrictions may apply.


Skull and crossbonesEnvironment

Signal Word


Hazard Statements

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Chronic 2

Storage Class Code

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials



Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24...
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping...
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)
Serge Gauthier et al.
Current medical research and opinion, 29(8), 989-1000 (2013-05-08)
To assess the real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease (AD) in Canada. Eighteen-month observational, prospective, multi-center, open-label study conducted on AD patients with Standardized Mini-Mental State Examination (SMMSE) score of 10-26...
Andrea C Tricco et al.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 185(16), 1393-1401 (2013-09-18)
Cognitive enhancers, including cholinesterase inhibitors and memantine, are used to treat dementia, but their effectiveness for mild cognitive impairment is unclear. We conducted a systematic review to examine the efficacy and safety of cognitive enhancers for mild cognitive impairment. Our...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service